2023

In May the FDA approved expanded labeling for Caldolor, an intravenously delivered formulation of ibuprofen, to include use in infants. The non-narcotic agent may now be administered for the treatment of pain and fever in patients 3 to 6 months of age.

Cumberland shared the positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor in newborns, published in the journal Pediatric Drugs. The results demonstrate that Caldolor is a safe therapeutic option available to practitioners for the treatment of fever and pain in infants, children, and adults.

In June 2023 Cumberland expanded the oncology sales division to deliver the newest brand Sancuso® – to help cancer patients tolerate their chemotherapy treatments. Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy.

In October a new publication in Antimicrobial Agents and Chemotherapy was announced detailing the results of the first clinical study investigating the safety and pharmacokinetics of the Vibativ product in children 2 to 17 years of age.

2022

In January 2022 Cumberland acquired the U.S. rights, from Japan-based Kyowa Kirin, to Sancuso, the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. To support Sancuso, a dedicated oncology sales division was established, Cumberland Oncology.

In March 2022 Cumberland Entered into a new agreement for Vibativ in the Middle East and established distribution for the Vibativ product in the Middle East, through a partnership with Tabuk Pharmaceutical Manufacturing Company. Tabuk will introduce the product in Saudi Arabia, Jordan, and potentially other countries in the Middle East.

Cumberland announced a new partnership for Mexico with PiSa Pharmaceutical for the registration and commercialization of Caldolor in October of 2022. Caldolor is Cumberland’s non-narcotic pain relief product that can also considerably reduce the need for post-operative opioids and potential for opioid addiction.

In November 2022 Cumberland opened new headquarters at the Broadwest campus in the Vanderbilt/West End corridor of Nashville. The move allows the company to accommodate growth, support the team, and better serve their international base of customers and partners.

2021

In May of 2021 Cumberland named John Hamm new Chief Financial Officer.

In June Cumberland announced Vibativ® effectively helps treat secondary bacterial infections in COVID-19 patients.

In November Cumberland announced the Corporate Headquarters will move to Broadwest. Cumberland announced that Caldolor® is now FDA approved for pre-operative administration. In January Cumberland announced that Sancuso® was acquired from Kyowa Kirin North America.

2019

Received FDA Orphan Drug Grant Funding and initiated clinical program to study ifetroban in patients with Duchenne Muscular Dystrophy.

Obtained FDA approval for Next Generation Caldolor^® product featuring a new patented formulation and improved packaging.

Completed a company-wide strategic review of products, partners, and organization.

2018

In January 2018, Cumberland Pharmaceuticals launches the Cumberland Pharma Foundation to organize and facilitate its ongoing philanthropic endeavors to various non-for-profit organizations whose activites align with Cumberland’s mission.

A new published study demonstrates the superiority of Caldolor^® over IV acetaminophen in reduction of post-surgical pain and opioid use. Data also supports the preemptive use of Caldolor^® in reducing pain and reliance on opioids post-surgery.

In November 2018, Cumberland enters into an agreement to acquire Vibativ^® (telavancin) for injection.

2017

In January 2017, the U.S. Court of Appeals affirms Cumberland Pharmaceuticals’ victory in patent litigation case associated with its Acetadote^® product.

Decmber 2017, Nashville Business Journal features Cumberland as the fastest growing Nashville health care company of 2017.

2016

Cumberland announces new development program to develop Vasculan^® oral capsule for the treatment of systemic sclerosis.

2015

Cumberland announces the approval of Caldolor^® (ibuprofen) Injection for pediatric patients six months of age and older.

2014

Cumberland announces fifth commercial product Vaprisol^® for the treatment of hyponatremia.

2012

Cumberland is named to Modern Healthcare’s Inaugural Healthcare’s Hottest List honoring healthcare’s 40 fastest growing healthcare companies.

Cumberland Pharmaceuticals is named as a finalist in the Nashville Business Journal’s “Best in Business” competition.

2011

Cumberland Pharmaceuticals named to as one of the Fastest Growing Companies in North America on Deloitte's 2011 Technology Fast 500™ list for the second consecutive year.

In November 2011, Cumberland reached an agreement to acquire the FDA registration and trademark for Kristalose^®.

Cumberland Pharmaceuticals launches next generation Acetadote^® product.

2010

Cumberland CEO A.J. Kazimi is named a finalist for Ernst & Young’s Entrepreneur Of The Year^® award in Alabama/Georgia/Tennessee for the second consecutive year.

Cumberland Pharmaceuticals is once again recognized as a finalist in the Nashville Business Journal’s Best in Business competition.

2009

Cumberland launches Caldolor^® the first injectable treatment for pain and fever approved in the U.S.

Cumberland completes Initial Public Offering  and share listing on NASDAQ exchange.

2006

Cumberland is named to the Inc. 500 list of America’s fastest growing private companies.

Cumberland launches co-promotion of Kristalose^® the only prescription laxative product available in a powder formulation for the treatment of acute and chronic constipation.

2005

Cumberland is named to Business Tennessee magazine’s Fast 50 list for a second year in a row.

Cumberland is honored with a Music City Future 50 Award, which recognizes the region’s most successful private companies.

2004

Cumberland is recognized as one of Business Tennessee magazine’s fastest growing 50 private companies.

Cumberland Pharmaceuticals launches their first FDA approved product Acetadote^® for the treatment for Acetaminophen overdose.